ACCESSIBILITY

24/7

Headlines

14:00

Musk’s potential role as government efficiency czar stirs concerns over power consolidation

11:28

“Investors who have historically invested in Israel continue to invest and, in some cases, have doubled down”

08:54

Generative AI: The destructive power and opportunities in the geopolitical arena

17:01

OneStep secures $36 million Series B for smartphone-based motion analysis technology

Buzz

Most popular

Daily

Weekly

Wiz will be bigger than CrowdStrike and Palo Alto: Cyber decacorn's top female executive shares her vision

BiltOn, founded by ex-Sayeret Matkal officers, nets $15M Series B for construction site platform

Cyberstarts nets $60 million for fourth Seed fund

Fintech startup Obligo raises $35 million for security deposit solutions

OneStep secures $36 million Series B for smartphone-based motion analysis technology

More news

Teva

20 stories about Teva

Teva to pay $450 million over Copaxone price inflation

11.10.24|Sophie Shulman

Settlement with the Department of Justice addresses price hikes from $17,000 to $85,000 per year for the multiple sclerosis drug.

לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva's vision 2025: Building on momentum for future market leadership

04.08.24|Sophie Shulman

Richard Francis’ strategic plan aims to transform Teva into a powerhouse of growth and innovation.

Teva posts impressive Q2 results, ups 2024 revenue forecast

31.07.24|Sophie Shulman

Strong sales of Austedo and Ajovy lead to double-digit growth for the Israeli pharma company.

How Monday overtook NICE and why Teva is on course to becoming Israel's highest-valued company

24.07.24|Sophie Shulman

While Wall Street transitions from growth stocks to value stocks, the balance of power among Israeli giants is also shifting. This reflects the speed at which the market punishes companies and rewards those leading growth processes, returning to profitability, or correctly identifying emerging fields.

מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva settles $750 million tax dispute with Israeli authorities

25.06.24|Sophie Shulman

The deal with the Israel Tax Authority resolves all pending litigation related to taxes payable for the years from 2008 to 2020

Teva shares continue to surge, climb to highest mark in more than five years on Q1 results

08.05.24|Sophie Shulman

AUSTEDO continues to be Teva's main growth engine and its flagship drug, with annual growth of 67% in sales

Why are Teva shares surging and how does it plan to keep it up

04.04.24|Uri Tel Tenne

Since the beginning of the year, Teva's shares have risen by about 36%, and are among the best performing stocks on the Tel Aviv Stock Exchange. Why is this happening and how is the company's CEO planning to build on the momentum?

Teva has sights on $12.2 billion Humira market after receiving FDA approval for arthritis injection

25.02.24|Meir Orbach

The Israeli pharma company and Iceland’s Alvotech announced that the SIMLANDI injection has been approved as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman

Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory

ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Teva expects lower profits in 2024 despite a strong Q4 performance

31.01.24|Reuters

"We are gaining momentum, and now it's about executing as we did in 2023 in 2024," said CEO Richard Francis

Teva CEO: Israel’s production capacity has not been affected by the war

08.11.23|Sophie Shulman

The Israeli pharmaceutical company’s revenues grew by 7% in the last quarter to $3.9 billion, according to a report it recently published.

יונתן קולבר, מנהל שותף של ION מפעל טבע בכפר סבא

$300 million Teva bet: Will Norway's wealth fund and ION regret investing in the pharma giant?

11.09.23|Almog Azar

ION, which manages investments for the Norwegian wealth fund, began a buying spree of Teva shares at the beginning of the year

Closure of another criminal case will help Teva's new CEO to focus on return to growth

22.08.23|Sophie Shulman

The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations

Teva profit plummets, stock slides

10.05.23|Reuters

Teva plans to unveil a new strategy next week which CEO Francis said would "build on Teva's strong foundations, key strengths, and sets the stage for long-term growth"

Schultz kept Teva away from the abyss, but couldn't find a runway to growth

22.11.22|Sophie Shulman

Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines

Teva names Richard Francis as new CEO after Kåre Schultz departure

21.11.22|CTech

Francis is the former CEO of Sandoz and was also a senior executive at Biogen for 13 years

Why are investors so pleased about Teva's $4.35 billion opioid settlement?

27.07.22|Sophie Shulman

The settlement removes the cloud of uncertainty that hovered over Teva, which on the one hand prevented investors from placing trust in its stock, while on the other hand also prevented Teva management from making substantial moves

Teva reaches $4.35 billion settlement in U.S. opioid lawsuits, shares surge

27.07.22|Sophie Shulman and Reuters

Teva is set to pay state and local governments up to $3.7 billion in cash over 13 years plus a contribution of $1.2 billion worth of the opioid overdose reversal drug naloxone

Amalia Adler-Waxman Teva Pharmaceuticals 20

“You have to walk the talk and have proof for everything that you say.”

08.02.22|CTech

Now vice president of Environmental, Social and Governance at Teva Pharmaceuticals, Amalia Adler-Waxman says that doing good requires being conscious and strategic

Ichilov Hospital and Sanara Ventures to join forces to promote innovation in neurology

12.10.21|CTech

The investment platform will invest in the hospital’s innovative technologies, giving it the opportunity to identify early-stage startups in the fields of neurology, digital health